← board
AMRN
distress 2/10 · well-funded / low risk$13.63-1%today-33% from 52w high
Lead: cardiovascular risk reduction
Revenue
$45M
Liquidity
$308M
Runway
—
Shares 1y
-100%
Price & events
-17.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-3.9%
1W
-14.7%
1M
-6.6%
3M
-16.2%
6M
-12.6%
1Y
-13.7%
2Y
-83.0%
5Y
-86.5%
All
Overview
- Market Cap
- $5.19M
- Volume
- 2.09K
- 52 Week Range
- $13.50 – $20.25
- Total Shares
- 380.69K
- Float Shares
- 18.56M
- Short %
- 2.64%
- % Held by Insiders
- 37.88%
- % Held by Institutions
- 22.88%
- RVOL
- 0.03x
- Beta
- 0.80
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-06-20partnershipVAZKEPA (icosapent ethyl) · Exclusive long-term license and supply agreement with Recordati for 59 European countries, including $25M upfront and up to $150M in milestones.SEC 8-K
- March 2025conferencedata presentationsecondaryVASCEPA/VAZKEPA · Presentation of additional data on EPA at ACC.25SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
sell · target $12 (-12% upside) · 1 analysts
- 2025-06-25Goldman SachsSell
- 2025-04-17Goldman SachsSell
Competitors — cardiovascular risk reduction
- none identified
Recent news
- 2026-07-16AMRN Technical Analysis & ETF Price Forecast - Intellectia AI
- 2026-07-15Amarin (AMRN) COO Keenan details RSU vesting and ADS tax withholding - Stock Titan
- 2026-07-15Amarin (NASDAQ: AMRN) CLO gets RSU shares; some withheld for tax - Stock Titan
- 2026-07-15Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 - GlobeNewswire
- 2026-07-14The Technical Signals Behind (AMRN) That Institutions Follow - Stock Traders Daily
- 2026-07-11Bears are losing control over Amarin (AMRN), here's why it's a 'buy' now - MSN
- 2026-07-10Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now - Yahoo Finance
- 2026-07-07Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming (NASDAQ:AMRN) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.